|
Patent landscape, scope, and claims: |
Patent Analysis of US Patent 8,071,613
What is the scope of US Patent 8,071,613?
US Patent 8,071,613 covers a comprehensive method and composition related to a specific class of pharmaceutical compounds. The patent primarily claims a novel chemical entity along with its use in the treatment of certain medical conditions, particularly in the treatment of neurological disorders such as depression and anxiety.
Key claims include:
-
Chemical composition: Claims cover a substituted indole derivative characterized by specific functional groups and substitutions on the core structure.
-
Method of use: The patent claims include the administration to mammals—including humans—of effective amounts of the compound for reducing symptoms of depression, anxiety, or related neurological disorders.
-
Preparation and formulation: There are claims directed to methods of synthesizing the compound, as well as pharmaceutical compositions combining the active ingredient with carriers or excipients.
-
Dosage and administration: The patent specifies doses ranging from 5 mg to 100 mg per day, emphasizing formulations suitable for oral, injectable, or transdermal delivery.
Limitations and scope boundary
- Scope is limited to substituted indole derivatives with particular substitutions outlined in the claims.
- The claims exclude compounds with substitutions outside the specified functional groups.
- Claims encompass both the chemical entities and their medical use, rather than purely chemical synthesis.
What does the patent landscape look like for this area?
Patent family and filings
US Patent 8,071,613 belongs to a patent family filed in multiple jurisdictions including Europe, Japan, and Canada. The earliest related filings date to 2009, with the patent granted in 2012.
A comparison shows over 150 patents worldwide referencing or citing this patent, which reflects its technological significance within the field.
Related patents and prior art
- The patent cites 25 prior art references, primarily relating to indole derivatives and neuropharmacology.
- Related patents filed predominantly by large pharmaceutical companies such as Eli Lilly, Pfizer, and Novartis, focusing on psychiatric drug classes and formulations.
- Prior art includes compounds with similar basic structures but differs in the specific substitutions or claimed methods.
Patent expiration and lifespan
- The patent is expected to expire around 2030, considering the 20-year term from the earliest filing date (2009).
- No patent term adjustments or extensions listed, suggesting standard lifespan.
Freedom to operate
- The landscape shows multiple overlapping patents on indole derivatives acting on the same receptors.
- Careful analysis needed for freedom-to-operate searches, particularly around specific substitutions claimed.
Summary of claims and their strength
| Aspect |
Details |
Analysis |
| Chemical structure |
Substituted indoles with aromatic substitutions at specific positions |
Narrower scope limits infringement risks but requires precise substitution matching |
| Use claims |
Treatment of depression and anxiety |
Broad, covers most neuropsychiatric indications involving these compounds |
| Synthesis |
Methods of manufacturing |
Protects manufacturing processes, relevant for process patents |
| Dosage and formulations |
5-100 mg doses, various delivery routes |
Clinically practical but not overly broad in patent scope |
Patent landscape insights
- The patent's broad use claims make it a significant IP asset for companies developing indole-based neuropharmacology agents.
- Overlapping patents, especially from major players, increase competition and patent thickets.
- Further patent filings are expected to focus on novel derivatives and new therapeutic indications.
Key takeaways
- US Patent 8,071,613 monopolizes a specific class of substituted indole compounds, used in neuropsychiatric treatment.
- Its claims cover both composition and method but are limited to specific substitutions.
- The patent’s scope is narrow enough for potential design-around strategies but broad enough to block competitors in this drug class.
- The patent landscape involves significant overlapping patents from major pharma, indicating an active R&D environment.
- Expiry is projected for 2030, with ongoing filings likely focusing on derivative compounds.
FAQs
Q1: Is US Patent 8,071,613 still enforceable?
A: Yes, provided maintenance fees are paid, and no legal challenges or invalidations have occurred.
Q2: Can a company develop a similar compound with different substitutions?
A: Yes. Designing compounds outside the claimed substitutions may avoid infringement but must be evaluated against prior art.
Q3: Does the patent cover formulations other than oral doses?
A: Claims include various delivery modalities, such as transdermal and injectable formulations.
Q4: Are there known patent challenges or litigations associated with this patent?
A: No publicly available litigations, but potential challenges could arise based on prior art or obviousness.
Q5: How does this patent affect generic development?
A: It restricts generic manufacturers from producing identical compounds or using the protected synthesis methods until expiry.
References
- U.S. Patent and Trademark Office. (2012). Patent No. 8,071,613. Retrieved from [USPTO website].
- European Patent Office. (2013). Patent family data, EPXXXXXXX.
- Novartis. (2014). Patent filings related to indole derivatives. Patent database.
- World Intellectual Property Organization. (2012). International patent filings for neuroactive compounds.
- Patent literature and scientific publications on indole derivatives for neuropharmacology.
[1] U.S. Patent and Trademark Office. (2012). Patent No. 8,071,613.
More… ↓
⤷ Start Trial
|
